AL 721

Drug Profile

AL 721

Alternative Names: Altrigen

Latest Information Update: 02 Feb 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ethigen Corporation
  • Developer Ethigen Corporation; Penn Pharmaceutical Services; Polagus
  • Class Antivirals
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cervical cancer; Cystic fibrosis; HIV infections

Most Recent Events

  • 02 Feb 2001 Profile reviewed but no significant changes made
  • 20 Nov 2000 Discontinued-II for HIV infections treatment in United Kingdom (PO)
  • 03 Jun 1997 No-Development-Reported for Cervical cancer (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top